Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5 : a study from the Acute Leukemia Working Party of the EBMT

Show full item record



Permalink

http://hdl.handle.net/10138/313286

Citation

Poire , X , Labopin , M , Polge , E , Forcade , E , Ganser , A , Volin , L , Michallet , M , Blaise , D , Yakoub-Agha , I , Maertens , J , Richard Espiga , C , Cornelissen , J , Finke , J , Mohty , M , Esteve , J & Nagler , A 2020 , ' Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5 : a study from the Acute Leukemia Working Party of the EBMT ' , Haematologica , vol. 105 , no. 2 , pp. 414-423 . https://doi.org/10.3324/haematol.2019.216168

Title: Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5 : a study from the Acute Leukemia Working Party of the EBMT
Author: Poire, Xavier; Labopin, Myriam; Polge, Emmanuelle; Forcade, Edouard; Ganser, Arnold; Volin, Liisa; Michallet, Mauricette; Blaise, Didier; Yakoub-Agha, Ibrahim; Maertens, Johan; Richard Espiga, Carlos; Cornelissen, Jan; Finke, Jurgen; Mohty, Mohamad; Esteve, Jordi; Nagler, Arnon
Contributor: University of Helsinki, HUS Comprehensive Cancer Center
Date: 2020-01-31
Language: eng
Number of pages: 10
Belongs to series: Haematologica
ISSN: 0390-6078
URI: http://hdl.handle.net/10138/313286
Abstract: Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia (AML) is a common high-risk feature that is referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with AML harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three hundred and thirty-eight patients (67%) were in first remission and 142 (28%) had an active disease at time of allogeneic transplantation. The 2-year probabilities of overall survival and leukemia-free survival were 27% and 20%, respectively. The 2-year probability of treatment-related mortality was 20%. We identified four different cytogenetic groups according to additional abnormalities with prognostic impact: -5/5q- without complex karyotype, monosomal karyotype or abn(17p), -5/5q- within a complex karyotype, -5/5q- within a monosomal karyotype and the combination of -5/5q- with abn(17p). In multivariate analysis, factors associated with worse overall survival and leukemia-free survival across the four groups were active disease, age, monosomal karyotype, and abn(17p). The presence of -5/5q- without monosomal karyotype or abn(17p) was associated with a significantly better survival rate while -5/5q- in conjunction with monosomal karyotype or abn(17p) translated into a worse outcome. The patients harboring the combination of -5/5q- with abn(17p) showed very limited benefit from allogeneic transplantation.
Subject: RISK MYELODYSPLASTIC SYNDROMES
COMPLEX ABERRANT KARYOTYPE
1ST COMPLETE REMISSION
LENALIDOMIDE MAINTENANCE
PROGNOSTIC-SIGNIFICANCE
MARROW-TRANSPLANTATION
POSTREMISSION THERAPY
TP53 MUTATIONS
YOUNGER ADULTS
EUROPEAN GROUP
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
414.full.pdf 2.500Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record